Trial · NCT05371288
The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19
NCT05371288, Early phase 1, Withdrawn, University of California, Irvine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19. Trials, record NCT05371288. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05371288
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19
- NCT number
- NCT05371288
- Status
- Withdrawn
- Phases
- Early phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of California, Irvine
- Conditions
- COVID-19
- Interventions
- NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
- First posted
- 2022-05-12
- Last updated
- 2024-11-05
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC) | Symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy | With the goal of reversing symptoms of Post-Acute Sequelae of COVID, this outcome measure aims to evaluate changes in symptoms before and after therapy, and determining which, if any symptoms are improved in each arm of the trial. |
| Primary | Change in Quality of Life Using SF-36 Survey | Will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy | The SF-36 survey is a multipurpose, short-form health survey with 36 questions to evaluate health-related Quality of Life . It yields an eight-scale profile of scores as well as physical and mental health summary measures. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. |
| Primary | COVID Severity of Symptoms Questionnaire | Day 15, 28, end of months 2, 3, 4 | This will evaluate the changes in the severity of symptoms over time with treatment. |
| Primary | Change in Time to Clinical Recovery (TTCR) | Day 15 and 28 (month 1), and at the end of months 2, 3 and 4 | Starting on day one of subjects' treatment, subjects will be asked if symptoms have improved or worsened, and the time it took for symptoms to change since their last treatment: (0 \[no change\], +1 \[improved within 7 days\], + 2 \[improved within 14 days\], +3 \[improved within 28 days\] + 4 \[symptom resolved\]; - 1 \[worsened within 7 days\], -2 \[worsened within 14 days\], - 3 \[worsened within 28 days\], - 4 \[debilitating last 28 days\] |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05371288
GET https://conductscience.org/api/trials/v1/NCT05371288/registered